123 related articles for article (PubMed ID: 33416128)
1. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
2. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract][Full Text] [Related]
3. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
Keren L; Bosse M; Marquez D; Angoshtari R; Jain S; Varma S; Yang SR; Kurian A; Van Valen D; West R; Bendall SC; Angelo M
Cell; 2018 Sep; 174(6):1373-1387.e19. PubMed ID: 30193111
[TBL] [Abstract][Full Text] [Related]
4. Frequency of Programmed Death Receptor Ligand 1 Expression and Clinicopathological Factors Associated With Metastatic Triple-Negative Breast Cancer at a Tertiary Cancer Care Centre in South India.
Babu S; Choudhary A; Jacob L; K N L; A H R; L K R; Saldanha S; Amirtham U; C R V
Cureus; 2024 Mar; 16(3):e55880. PubMed ID: 38595897
[TBL] [Abstract][Full Text] [Related]
5. PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems.
Muscatello LV; Gobbo F; Avallone G; Innao M; Benazzi C; D'Annunzio G; Romaniello D; Orioles M; Lauriola M; Sarli G
Vet Pathol; 2024 May; 61(3):393-401. PubMed ID: 37920996
[TBL] [Abstract][Full Text] [Related]
6. SCGB2A2 as a predictor of prognosis and response to immune-checkpoint blockage in metastatic triple-negative invasive breast cancer.
Zheng Y; Peng Y
Asian J Surg; 2024 May; 47(5):2299-2301. PubMed ID: 38378431
[No Abstract] [Full Text] [Related]
7. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
8. Comment on "Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta‑Analysis".
Ma J; Han W
Mol Diagn Ther; 2024 May; 28(3):345-346. PubMed ID: 38600343
[No Abstract] [Full Text] [Related]
9. Immunotherapeutic strategies in breast cancer: A clinical update.
Zhang JQ; Plitas G
J Surg Oncol; 2021 Mar; 123(3):710-717. PubMed ID: 33155281
[TBL] [Abstract][Full Text] [Related]
10. Truncated PD1 Engineered Gas-Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells.
Zhang S; Liang Y; Ji P; Zheng R; Lu F; Hou G; Yang G; Yuan L
Adv Sci (Weinh); 2024 Mar; 11(12):e2305891. PubMed ID: 38263860
[TBL] [Abstract][Full Text] [Related]
11. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
[TBL] [Abstract][Full Text] [Related]
13. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Triple-Negative Breast Cancer.
Emens LA
Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
16. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.
Dieci MV; Miglietta F; Guarneri V
Cells; 2021 Jan; 10(2):. PubMed ID: 33498711
[TBL] [Abstract][Full Text] [Related]
17. Analysis of clinical effect of PD-1 inhibitor combined with chemotherapy in the treatment of nasal type NK/T cell lymphoma.
Fu J; Yin X; Ma Q
Panminerva Med; 2021 Jan; ():. PubMed ID: 33494564
[No Abstract] [Full Text] [Related]
18. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.
Pallerla S; Abdul AURM; Comeau J; Jois S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466691
[TBL] [Abstract][Full Text] [Related]
19. Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Wu HJ; Chu PY
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435254
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
